AgingResearch.NewsJoin free

Exela Pharma Sciences

CompanyUnited States

Exela Pharma Sciences develops one asset, in phase 3 (EXL CDOS in acute otitis externa). Mostly small molecule acting on NR3C1, inflammation and TOP2A; based in the United States.

1
Asset
Furthest stage
Phase 3
1
Trial
0
Signals

Pipeline

1

  • EXL CDOS

    Topical antibacterial and anti-inflammatory combination of ciprofloxacin and dexamethasone.

    Phase 3, Small molecule, NR3C1, Inflammation, acute otitis externa

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms4
  • Trials1
  • Similar companies6

Intelligence